In patient-derived immunocompetent cultures(iPDCs), monotherapy with anti-TIGIT or combination therapy with anti-PD-1(pembrolizumab) can significantly enhance the expression of granzyme B and IFN-γ in CD8+T cells in samples after chemotherapy, activating the anti-tumor function of T cells, and the treatment response is more significant in samples with high expression of NECTIN2-TIGIT (65). Here, TIGIT is linked to neoplasm.